An interventional study of NHGDoc domain Heart Failure in Heart Failure, sponsored by Radboud University Medical Center. Completed at 1 site in Netherlands. Per ClinicalTrials.gov, last updated 2018-04-12.
Sponsored by Radboud University Medical Center · Not applicable, Interventional, and Treatment
The purpose of this study is to determine whether the computerized decision support system 'NHGDoc' is effective in improving quality of primary care in terms of processes of care (e.g. prescribing behavior of physicians) as well as outcomes of care (e.g. hospital admissions, mortality).
Computerized decision support systems are regarded as useful tools to improve quality of care, but their effects are still uncertain. In the Netherlands 'NHGDoc' a computerized decision support system supported by the Dutch College of General Practitioners (NHG) is currently being implemented among more than 1.000 general practices in the Netherlands.
The aim of this study is to evaluate the effects of NHGDoc on quality of care. In addition, we want to gain insight into the barriers and facilitators that affect the systems' impact.
A cluster randomized controlled trial will be conducted among 120 general practices in the Netherlands. Eligible practices will be randomized to receive either the regular NHGDoc modules (control arm) or the regular modules and an additional module on heart failure (intervention arm). The effect evaluation will focus on processes of care (e.g. prescription behavior) as well as on patient outcomes (e.g. hospital admissions, mortality). Additionally, a process evaluation will be conducted, which includes a focus group study and a survey among participating healthcare providers to evaluate the perceived barriers and facilitators to using 'NHGDoc'.
Results of this study will provide insight in the ability of computerized decision support systems and in particular 'NHGDoc' to improve quality of primary care. Whereas the trial focuses on a specific NHGDoc domain - heart failure - we believe our conclusions are relevant to other primary care areas as well, particularly as this study also explores the factors that contribute to the systems' effectiveness.
5,701 studies on the registry are indexed under Heart Failure; 1,220 are open to participants now.
This study's enrollment of 120 is above the median of 72 across 3,736 interventional studies indexed under Heart Failure.
Browse Heart Failure studies →Radboud University Medical Center is the lead sponsor of 959 studies on the registry; 134 are open to participants now.
Of its 6 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
Regular NHGDoc domains plus NHGDoc domain heart failure
Other: NHGDoc domain Heart Failure
Regular NHGDoc domains
Healthcare providers receive patient specific alerts in terms of diagnosing and treatment of patients with heart failure
Prescribing of ACE-inhibitors/Angiotensin II
Percentage of patients with heart failure that is prescribed ACE-inhibitors/Angiotensin II
Time frame: One year
Prescribing of beta blockers
Percentage of heart failure patients that is prescribed beta blockers
Time frame: One year
Prescribing of diuretics
Percentage of heart failure patients that is prescribed diuretics
Time frame: One year
Hospital admissions
Number of hospital admissions of patients with heart failure
Time frame: One year
All cause mortality
Number of patients with heart failure that die within the hospital
Time frame: One year
This study is completed, as verified in Oct 2016. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Radboud University Medical Center